HMNC Brain Health, a Munich, Germany-based clinical stage biopharma company, raised €14.3m in funding.
The round, which brought the total capital raised to date to €42.3m, was led by Carsten Maschmeyer, Jahr Group, and Guntard Gutmann, with participation from Dr. Josef Ackermann, Toni Kroos, Wilhelm Beier, and Hans Kompernaß.
The company intends to use the funds to accelerate its precision psychiatry programs, develop the Ketabon program, an oral prolonged release formulation of ketamine targeting treatment-resistant depression.
Led by CEO Dr. Maximilian Doebler, and Chief Business Officer Dr. Maximilian Doebler, HMNC Brain Health is a clinical stage precision psychiatry biopharma company, developing personalized therapies, powered by its AI platform and predictive companion diagnostics suite, bringing substantial therapeutic benefit to select patient populations suffering from mental health disorders. The company develops a pipeline for targeting both Major Depressive Disorder and Treatment-Resistant Depression. Its precision psychiatry franchise for MDD includes the Nelivabon program, in which it develops a V1bR antagonist with its companion diagnostic, and the Cortibon program, in which it develops a CRHR1 antagonist with its companion diagnostic. Additionally, in a joint venture with Develco Pharma, the company is also developing an oral-prolonged release formulation of racemic ketamine that combines the rapid efficacy of ketamine with superior tolerability and convenience, to provide an enhanced treatment option for TRD.
HMNC Brain Health expects to complete a second closing of this round by end of March 2023.
FinSMEs
21/10/2022